vimarsana.com
Home
Live Updates
89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023 : vimarsana.com
89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023
—Reductions in key non-invasive tests of liver inflammation and fibrosis support previously demonstrated fibrosis improvements across compensated cirrhotic patients at week 24— —A...
Related Keywords
San Francisco
,
California
,
United States
,
Boston
,
Massachusetts
,
Sheryl Seapy
,
Annie Chang
,
Hank Mansbach
,
Linkedin
,
Drug Administration
,
Lifesci Advisors
,
Globenewswire Inc
,
Nasdaq
,
Exchange Commission
,
Liver Meeting
,
Chief Medical Officer
,
Non Invasive Tests
,
Breakthrough Therapy
,
England Journal
,
Breakthrough Therapy Designation
,
Annual Report
,
Safe Harbor
,
Private Securities Litigation Reform Act
,
Sci Advisors
,
Markets
,
vimarsana.com © 2020. All Rights Reserved.